Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Spero Therapeutics, Inc. | CFO & CBO | Common Stock | 379K | $493K | $1.30 | Nov 8, 2024 | Direct |
Fulcrum Therapeutics, Inc. | Chief Financial Officer | Stock Option (right to buy) | 160K | Feb 9, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
SPRO | Spero Therapeutics, Inc. | Nov 7, 2024 | 2 | -$53K | 4 | Nov 12, 2024 | CFO & CBO |
SPRO | Spero Therapeutics, Inc. | Feb 1, 2024 | 1 | $0 | 4 | Feb 5, 2024 | Chief Financial Officer and Chief Business Officer |
SPRO | Spero Therapeutics, Inc. | Nov 13, 2023 | 1 | $0 | 4 | Nov 15, 2023 | Chief Financial Officer and Chief Business Officer |
SPRO | Spero Therapeutics, Inc. | Nov 6, 2023 | 0 | $0 | 3 | Nov 15, 2023 | Chief Financial Officer and Chief Business Officer Exhibit 24.1 - Power of Attorney |
FULC | Fulcrum Therapeutics, Inc. | Feb 9, 2023 | 1 | $0 | 4 | Feb 13, 2023 | Chief Financial Officer |
FULC | Fulcrum Therapeutics, Inc. | Jan 3, 2022 | 1 | $0 | 4 | Jan 10, 2022 | Chief Financial Officer |
FULC | Fulcrum Therapeutics, Inc. | Jan 3, 2022 | 0 | $0 | 3 | Jan 10, 2022 | Chief Financial Officer |